April 2022 Top Biopharma Deal: Harbour BioMed – AstraZeneca Bispecific Antibody for Cancer Treatment

May 9, 2022 | Deal of the Month, Partnership Deals

April 2022 Top Biopharma Deal Upfront
Harbour BioMed development and commercialization deal with AstraZeneca for solid tumors

Highlighted Deal Financial Comps

Date Announced:

April 6, 2022

Total Deal Value:


Upfront Cash:


Upfront Equity:


Option Payments:


Total Milestones:

up to $325M


Undisclosed tiered royalties

Cost & Profit Split:


Deal Synopsis

The Asset:

Harbour BioMed’s HBM7022 CLDN18.2xCD3 bispecific antibody for solid tumors, including gastric and pancreatic cancers

Deal Structure:

Development and Commercial License

Partnership Features:

Collaborative Development, No Shared Cost

Deal Details:

  • Harbour BioMed granted AstraZeneca exclusive, worldwide rights to develop and commercialize its HBM7022 CLDN18.2xCD3 bispecific antibody developed using HBM’s HCAb based Immune Cell Engagers (HBICE) platform for the treatment of solid tumors, including gastric and pancreatic cancer.
  • AstraZeneca will be responsible for all costs for development and commercialization.
  • HBM will receive $25M up front and is eligible for up to $325M in development, regulatory, and commercial milestones, plus undisclosed tiered royalties.

Last Month:

Congrats to Harbour BioMed and AstraZeneca for landing DealForma’s April 2022 Top Biopharma Deal. Last month’s Deal of the Month was IGM Biosciences – Sanofi IgM antibody platform for Cancer and immunology/inflammation treatment. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.


Licensing Deals


Funding Rounds




Company Profiles


Other Deals


Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Introducing: DealForma plus Tableau

Introducing: DealForma plus Tableau

We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...

Venture & IPO – Medtech – Q1 2023 

Venture & IPO – Medtech – Q1 2023 

The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...